Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Eli Lilly (LLY) is one of Nvidia's (NVDA) many partners announced by the artificial intelligence (AI) chipmaker. The two ...

On Wednesday, Lilly said Zepbound would be sold directly in Walmart pharmacies for $349 to $499 a month. Next year, Lilly is ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

This week's dividend activity included increased payouts from Visa ( V) and Marathon Petroleum ( MRC) as well as declarations ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...